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for analyzing data and p-values Results: Thirty-eight patients were included and 
the common infection types are pneumonia (N= 13); UTI (N= 12); cellutitis (N= 9) and 
sepsis (N= 9). The common pathogens are Staphylococci (19%) and Pseudomona species 
(21%). Twenty-one percent of cases used UFO® as empirical or first-line therapy. 
Combination therapies with cephalosporins (26%) or penicillins (24%) were more 
frequent. In cephalosporins combinination therapy, the most combined antibiot-
ics are 3th cephalosporins (75%). In penicillins combinination therapy, the most 
combined antibiotics is oxacillin (40%). Mean treatment duration of UFO is 9.4 days. 
There were 71% cases using common dose of UFO®, 8-12 g/day, and 29% using 
low dose, 4-6 g/day. In patients with UFO®, 74% had negative outcomes (defined 
as patient died, hypernatremia events and changed to other antibiotics) and 26% 
had positive outcomes (defined as patients discharged, disease improved and no 
recurrent fever). Most patients developed hypernatremia (serum sodium level > 145 
mEq/L) after using UFO® for 4-6 days; patients with creatinine clearance above 50 
ml/min did not develop hypernatremia. ConClusions: The serum sodium level 
didn’t increase significantly until day 4-6 after starting UFO®. For patients with 
higher baseline serum sodium level and renal dysfunction, sodium level should be 
monitored closely while using UFO®. Using UFO® as adjunct for first line or empiric 
treatments is lack of evidence. Further antibiotic prescribing regulations should be 
implemented concerning prescribing UFO®.
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objeCtives: Drugs retail outlets constitute a major source of malaria treatment 
in developing countries requiring regular and accurate information for enhanc-
ing strategies for improving the use of Artemisinin-based Combination Therapy 
(ACT). The study analyzed the demand and sales pattern of antimalarial drugs in 
private retail outlets to assess the current state of compliance to policy. Methods: 
A prospective cross-sectional survey of randomly selected drugs retail outlets in 
Enugu urban, south east Nigeria, was conducted between May and August, 2013, to 
determine the types, range, prices and sales pattern of antimalarial drugs as well 
as concomitant medications, from pharmacies and patent medicine outlets. Data 
was collected and analysed for antimalarial drugs demanded for and sold by self-
medication, treatment by retail outlets and prescription from hospitals. Results: 
With a total of 1,321 dispensed antimalarial drugs, ACTs accounted for 72.7% while 
monotherapy was 27.3%. AMFm drugs contributed 32.7% (n = 314) of ACTs. 46.5% 
(614) of the drugs were dispensed from self-treatment by patients. Treatment by the 
retail outlets accounted for 35.8% (n = 473) while 17.7% of the drugs were dispensed 
from hospital prescriptions. The median cost of the ACTs, at $3.23 is about three 
times the median cost of monotherapy ($0.97). Total cost of treatment, including 
concomitant medications averaged $3.34 (±$1.90). The AL brand was the most used 
ACT, at 69.3% (n = 666). Self-medication accounted for the highest number of mono-
therapy at 82% ConClusions: The use of ACTs as predominant antimalarial drugs 
of choice has become widespread in the retail outlets, with significant contribu-
tions from AMFm drugs. This portends positive implications on the implementation 
of antimalarial drugs policy. However costs of policy recommended drugs remain 
higher than intended and the use of monotherapy particularly through self-med-
ication is significant suggesting additional measures to directly target consumers 
for improved use of antimalarial drugs.
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objeCtives: To describe current utilization of HIV drugs in Canada. Methods: 
Longitudinal pharmacy retail data were obtained from most Canadian provinces. 
Eligible patients received their first HIV drug prescription during the selection 
period, and consistently filled subsequent prescriptions at the same pharmacy. 
Selection periods included an early cohort (initiating therapy January 2008 to 
July 2009) and a late cohort (initiating therapy August 2010 to February 2012). The 
observation period was 43 months for the early cohort and 12 months for the late 
cohort. Results: 905 patients in the early cohort and 1,411 patients in the late 
cohort were analysed. Single-tablet regimens were the initial therapy for 32% of 
patients (early cohort) and 33% (late cohort). The most commonly used regimen 
was a backbone + protease inhibitor (PI): 45% of total days on therapy (DOT) for early 
cohort, 39% for late. Darunavir was increasingly chosen as the initial PI (3% patients 
for early cohort, 16% for late). Backbone plus integrase inhibitor (II) increased from 
2% DOT (early cohort) to 11% in the late cohort. The majority of II patients were 
treatment-naïve (71%) in the late cohort, despite funding limitation to treatment-
experienced patients in most jurisdictions. After 3 years of follow-up in the early 
cohort, 45% were still on their first therapy. For early-cohort patients who switched 
to a second therapy, 33% did so within 3 months. Subsequent lines of therapy phased 
in more gradually in both cohorts. Darunavir and II use increased in later lines of 
therapy for both cohorts, but particularly for the late cohort. ConClusions: This 
research documented changing patterns for HIV drug use in Canada, with increasing 
use of darunavir and II over time (irrespective of funding restrictions) and frequent 
early therapy switches suggestive of tolerability issues.
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treatment effectiveness, recurrence rates, mortality rates, and costs. Results: In 
the general population 5% -20% of adults are estimated to be asymptomatic carri-
ers of CDI but up to 80% of the elderly in LTCF are colonized. Over 50% of cases are 
associated with hospitals and LTCFs. Growing number of cases have onset in the 
community. 9% of patients over 65 experience severe episodes compared to 4% for 
those below 65. Mortality rates for elderly are much higher. Patients over 65 experi-
ence almost twice the recurrence rate (38%), compared with younger populations 
(18% -22%). The rates for a second recurrence are 38% for those 65+ versus 24% 
below 65. The probability of recurrent CDI increases with the number of recurrences 
experienced. Recurrences were associated with major increases in hospital LOS and 
in costs. ConClusions: Our age-specific model allows to project and to quantify 
the impact of a CDI outbreak in terms of clinical burden and costs. Using a scenario-
based approach, comparisons of current treatments with the novel approach of 
duodenal infusion (fecal transplant) are carried out.
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bACkgRound: Children 6 months through 18 years of age are consistently identified 
as a high-risk population for influenza infections. Since 2007, the Advisory Committee 
on Immunization Practices (ACIP) emphasized children aged 6 months to < 9 years 
receive two doses of influenza vaccine in a season. Poor compliance with this two-
dose regimen has been described in recent years. However, since ACIPs two-dose 
recommendation in 2007, predictors of two-dose compliance have not been assessed 
using population-based data. objeCtives: This study analyzed data from influenza 
seasons 2008-2011 to examine two-dose compliance for children aged 19-35 months. 
This analysis tests for significant demographic and socioeconomic differences in one- 
and two-dose influenza vaccinations. Methods: Seasonal influenza vaccinations of 
children were estimated from the National Immunization Survey (NIS). The analysis 
results were nationally representative by weighting the study population according 
to survey weights and cluster variables. Primary outcome measures were at least one 
dose and two doses of influenza vaccination during September 1 through December 
31 of the season. For each season, the proportion of children with partial and full 
influenza vaccinations were calculated. Multivariate regressions modeled the effect 
of multiple NIS factors (i.e., age, race, gender) on influenza vaccination. Results: 
For all four seasons, adjusted one-dose influenza vaccination was significantly lower 
among children 24-35 months compared to children 19-23 months (ranging from 
7.8-44.5%, p< 0.05). Furthermore, one- and two-dose influenza vaccination was lowest 
among children living below the poverty level compared to children living above the 
poverty level (ranging from 9.4-53.7%, p< 0.05). ConClusions: Policies to improve 
one- and two-dose influenza vaccination rates should target children living below 
the poverty level. Efforts to improve one-dose vaccination rates among older infant 
children should continue. Further studies are needed to determine the reasons for 
initiating influenza vaccinations among children less than 24 months of age.
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objeCtives: This study aimed to evaluate if high antibiotic consumption is explained 
by inappropriate prescribing, given current practice guidelines. This is assessed 
through measuring the proportion of Upper Respiratory Tract Infection (URTI) treated 
by GPs with Co-amoxiclav, and Urinary Tract Infection (UTI) treated with fluoroqui-
nolones, comparing across population subgroups for differential treatment pat-
terns. Methods: This cohort study included records of all Clalit members visiting 
physicians from 4300 clinical practices during 2011. Rule-based algorithms were used 
to classify multiple primary care visits into discrete URTI and UTI events and link 
these with Ab prescriptions and dispensing. Infectious events and antibiotic prescrip-
tion rates were calculated. Differences in distributions across districts and population 
subgroups were then tested with Chi-square analysis; for prescribing ratios for UTI the 
ratio for prescribing fluoroquinolones vs. Nitrofurantoin (narrow-range Ab of choice) 
were calculated. Results: 6.5 million visits for infectious diagnoses were registered 
for all 4 million enrollees. Almost 75% of the Co-amixiclav dispensed was used for 
treatment of URTI, with 6% of URTI events treated with Co-amoxiclav. Over 75% of 
fluoroquinolones dispensed were used to treat UTI, with 23% of UTI events treated 
with fluoroquinolones. Variability between districts in the use of Co-amoxiclav for 
URTI ranged between 12%-23% in adults and 5%-21% in children. Twenty percent of 
physicians were co-amoxiclav “prescribers” with high rates of URTI events treated 
with co-amoxiclav (10%-38%). Treatment of UTI events with Quinolons varied con-
siderably between 19%-52%. The proportion of Quinolons\Nitrofurantoin prescribed 
ranged between 1.4 (1.3-1.5) to 6.2 (5.5-6.8) in each district. ConClusions: Rates 
of utilizing broad-spectrum antibiotics in the community are higher than expected 
and show wide variability across country districts and between physicians This sug-
gests the need for introducing this as a quality measure and implementing targeted 
interventions to reduce inappropriate antibiotic use.
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Taipei Medical University – Wan Fang Hospital, Taipei, Taiwan
objeCtives: To evaluate efficacy, safety (concerning hypernatremia), and usage 
of UFO® in a medical center Methods: A retrospective medical record review 
was conducted for patients who is treated with UFO® in Wan-fang hospital during 
2012/5/1 to 7/8. Patients with cancers were excluded. Patients with suspected or 
diagnosed infections and more than one dose of UFO® were included. For hyper-
natremia analysis, only included patients with serum sodium level and no hyper-
natremia events prior UFO use. Microsoft excels and student t-test were utilized 
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characteristics. ConClusions: Based on this analysis, substantial proportions of 
patients in Class II and III were not hospitalized, possibly reflecting a trend toward 
treatment of moderate ABSSSI patients in the ambulatory setting. Switching appro-
priate patients from inpatient to OPAT setting could potentially save the health 
system approximately $6,000-7,000/patient.
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objeCtives: To assess outcomes of clostridium difficile infection (CDI) and the 
association of expenditures and CDI in pediatric solid organ transplant (SOT) recipi-
ents. Methods: Data from the 2000, 2003, 2006, and 2009 Kids’ Inpatient Database 
(KID) files were used to identify events with SOT- related ICD-9-CM diagnosis codes. 
The data were evaluated using logistic regressions and log-linked gamma regres-
sions. Results: The total number of pediatric SOT hospital events was 48,286. 
The overall prevalence of CDI for pediatric SOT hospitalizations was 1.76%. For 
SOT hospitalizations with CDI, inpatient mortality was 1.63%; the prevalence of 
transplant failure or rejection events was 27.71%; the prevalence of a colectomy 
was 4.86%. The median LOS was seven days; the median charge for each hospitali-
zation was $48,409; and the median cost for each hospitalization was $17,412. The 
results showed that CDI was not significantly associated with inpatient mortality 
or transplant failure/ rejection in pediatric SOT hospitalizations, but the power 
to detect differences was low. SOT patients with CDI were 2.6 times more likely 
to have a colectomy than SOT patient without CDI (OR= 2.62, 95% CI= [1.63, 4.22], 
p< 0.001). The mean LOS for a SOT admission with CDI was approximately 2 times 
the mean LOS for a SOT admission without CDI (coefficient= 1.93, 95% CI= [1.68, 
2.21], p< 0.001). The mean charges and the mean costs for a SOT admission with 
CDI was approximately 2 times that for a SOT admission without CDI (charges: 
coefficient= 2.01, 95% CI= [1.63, 2.46], p< 0.001; costs: coefficient= 1.96, 95% CI= [1.50, 
2.58], p< 0.001). ConClusions: CDI diagnoses were not significantly associated 
with higher inpatient mortality or transplant failure/ rejection for pediatric SOT 
hospitalizations. But CDI was significantly associated with a higher prevalence of 
a colectomy, longer hospital LOS, higher charges, and higher costs.
PIN101
methODOlOgIcAl Issues AssOcIAteD WIth the use OF sOcIAl meDIA IN 
OutcOmes reseArch: cAse stuDy OF ADult vAccINAtION
Yang H.K.1, Abogunrin S.2, Cox A.2, Khankhel Z.2, Martin A.2, Merinopoulou E.2
1Merck & Co., Inc, West Point, PA, USA, 2Evidera, London, UK
objeCtives: Social media (SM) is increasingly being used as a data resource in 
published scientific literature to study disease burden and perceptions of patients 
and caregivers. However, the feasibility, ethics and legality of using SM in outcomes 
research remain unclear. We aimed to explore these issues in the context of adult 
vaccination. Methods: We searched the internet using different search engines 
and browsers to identify SM sites with content relevant to adult vaccination. We 
developed a decision-matrix based on weighted characteristics to determine which 
sites are most useful for in-depth data analysis. Thirty-five SM sites were scored for 
popularity, amount and type of content relevant to vaccination, data use restric-
tions, and feasibility of accessing the data. Results: SM sites with relevant content 
included general sites such as Facebook, Twitter, and YouTube; and health-specific 
sites such as HealthUnlocked, PatientsLikeMe, and SmartPatients. Although sev-
enteen sites facilitated access to their public-facing content via interfaces such as 
application programming interfaces (APIs), nine sites had limitations to the use of 
public content for non-personal reasons. Two sites did not support the download 
and storing of site content for in-depth analysis and audit, while data from most 
sites could only be downloaded manually or by automatic ‘scraping’. All selected 
sites facilitated responses to an initial post, but only a minority had examples 
of multi-user conversations or discussions about vaccination in adults. The sites 
with the most potential for in-depth data analysis were Google+, Twitter, YouTube, 
Yahoo Answers, and Facebook. ConClusions: Contrary to popular opinion, data 
that is available for all to browse and disseminate rapidly and globally is not always 
legally and practically accessible for research. Clarification of the issues around 
the use of SM for health research is needed to establish best practice guidance for 
this rich resource.
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objeCtives: Emergence of resistance towards almost all broad spectrum antibiot-
ics is rapidly increasing and one of the main causes is irrational and inappropriate 
prescription of carbapenems. Hence the current study was carried out to assess 
the prescribing pattern of carbapenems in medical intensive care unit of a private 
tertiary care hospital. Methods: A retrospective observational study was car-
ried out in patients prescribed with carbapenems in MICU for a period of 1 year. 
Only patients having stay of more than 24 hours were included in study. Results: 
Out of total 138 patients, 127 patients were included in the study as per protocol. 
Average age of patient was found to be 55.2 ± 1.684 years. Mean Acute Physiology 
and Chronic Health Evaluation (APACHE) – IV Score was 72.63 which show critical 
condition of the admitted patients. Fifty four percent patients were with severe 
sepsis and 32% were in septic shock. In 86 patients carbapenems were prescribed 
at first day of admission in ICU. Most of the prescribed drug was meropenem fol-
lowed by doripenem and imipenem. Mostly prescribed concomitant antimicrobials 
were glycopeptides, antifungals and metronidazole. Prescription and switching of 
antimicrobials was according to culture sensitivity reports in 97% cases. Survival 
outcome was 64%. ConClusions: Prescription of broad spectrum antimicrobials 
objeCtives: US Health Reform is stimulating new models of care, such as pharma-
cist vaccination programs. While pharmacist vaccination holds promise in improv-
ing access to this important preventive modality, evidence on these programs is still 
emerging. The objective of this research was to conduct a systematic review of pub-
lished evidence on pharmacist immunization programs for two common diseases-- 
influenza and pneumococcal disease. Methods: Ten PubMed literature searches 
were performed using the keywords pharmacist, vaccination, program, policy, cost, 
and education. Inclusion criteria: pharmacist administration of immunizations and 
published between 2000 and 2013. Exclusion criteria: student pharmacists used 
as immunizers and research was non-US. Results: 102 articles were identified. 
Of these, 52 met inclusion criteria; 30 (57.7%) were primary research, 22 (42.3%) 
were secondary research. Older adults (≥ age 65) were the most common target 
for pharmacist vaccination programs (21.2%), followed by 9.6% targeting a specific 
ethnicity, 7.7% targeting individuals with chronic conditions, and 5.8% targeting 
individuals at high risk for the disease. Patient-reported barriers to pharmacist vac-
cination included: accessibility to the pharmacist (42.3%), cost/insurance concerns 
(36.5%), lack of health care provider recommendation (19.2%), lack of awareness 
of the illness (15.4%), and fears that the vaccine will cause illness (11.5%). The lit-
erature lacked program cost and outcome data such as knowledge and vaccina-
tion rates. ConClusions: Though intuitively it would seem that pharmacists are 
highly accessible, the literature suggests that access to pharmacists is, instead, a 
barrier to vaccination, perhaps due to time limitations or physical infrastructure not 
conducive to vaccination. Cost or insufficient insurance coverage for pharmacist-
administered vaccines is also a concern. More evidence is needed on the outcomes 
of these programs in terms of improving pharmacist accessibility, vaccination rates 
and knowledge about the disease, as well as economic data to inform decision mak-
ers on their value in relation to traditional models of care.
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objeCtives: Immunization is a cost-effective strategy to reduce the impact of influ-
enza among elderly. The purpose of this study was to examine racial disparities in 
influenza vaccination in elderly after controlling for individual and higher level 
factors. Methods: The 2011 Behavioral Risk Factor Surveillance System Selected 
Metropolitan/Metropolitan Area Risk Trends (BRFSS SMART) dataset was used for 
this study. Study population consisted of individuals aged 65 years or above and 
those who responsded as either yes or no about having received seasonal flu shot/
spray during the last one year. Race, age, gender, education level, employment sta-
tus, marital status, health insurance coverage and medical cost were used as level 
1 variables. United States county code and race aggregated at level 2 were used as 
level 2 variables. Two-level logistic regression analysis was used to examine racial 
disparities in influenza vaccination in elderly. Results: The study cohort consisted 
of 66,165 subjects. Of these, 41,427 (62.61%) received influenza vaccination. Mean 
age of the study sample was 75 years (74.64 ± 7.20). Most of the elderly patients 
receiving influenza vaccination were females (64.09%), Whites (87.99%), and insured 
(99.86%). Results from multilevel modeling suggested that individuals’ race (odds 
ratio:1.289, p value < .0001), and other factors like age, gender, education level, 
employment status, marital status, health insurance coverage and medical cost 
were significantly associated with influenza vaccination in elderly. Effect of race 
varied significantly across counties for influenza vaccination in elderly. Additionally, 
county-level race moderated the effect of individual race for influenza vaccination 
in elderly. ConClusions: Racial disparities exist in influenza vaccination among 
elderly even after controlling for individual and higher level factors. Individual level 
factors were better predictors of influenza vaccination in elderly than the level 2 
factors. However, it is always desirable to use multilevel approach when the nature 
of the data is inherently nested.
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objeCtives: Acute bacterial skin and skin structure infections (ABSSSIs) are the 
second most common indication for antibiotic treatment. Eron et al. developed 
an algorithm for disease severity and appropriate treatment to optimize patient 
care and minimize costs. However, this algorithm has yet to be thoroughly vali-
dated in the real-world. The objectives of this study were to investigate the current 
ABSSSI patient population and compare the direct health care costs associated with 
inpatient versus outpatient parenteral antimicrobial therapy (OPAT) treatment, by 
patient severity level, in the US. Methods: ABSSSI patient characteristics were 
evaluated using the Premier Hospital Database. Standard data elements in hospital 
discharge files, including diagnoses and procedures categorized by International 
Classification of Diseases, Ninth Revision were used to classify patients according 
to the Eron classes I-IV. Data for this study were extracted from January to Dec 
2012. Results: There were 533,263 hospital and emergency room discharges with 
a principal diagnosis of ABSSSI included for analysis. The percentages of patients 
categorized as Eron Class I-IV were 73.47%, 20.15%, 4.75% and 1.63% respectively. 
20.35% of patients were hospitalized; 9.26%, 43.51%, 71.36% and 85.54% in Class I-IV 
respectively. The unadjusted costs associated with inpatient versus OPAT treat-
ment varied substantially by disease severity: mean costs were $5,729 inpatient vs. 
$368 OPAT for Class I, $7,651 vs. $634 for Class II, $10,339 vs. $823 for Class III, and 
$16,559 vs. $1,050 for Class IV. The cost increases for inpatient versus OPAT treat-
ment ranged from $6,303 to $7,351 for Class II and III after adjustment for baseline 
